All In Biotech

Drug Trial Radar · NCT07300943

Study in Advanced Solid Tumor Patients

A Phase 1/2 Study of CLIO-8221 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

306

Planned (sponsor's estimate)

Start

Mar 19, 2026

Primary completion

Dec 31, 2027

Study completion Jul 17, 2028

Sponsor

Lead sponsor
Callio TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor-specific expansion cohorts to optimize dosing and assess preliminary efficacy.

Conditions

  • Advanced Solid Tumor

Interventions

  • CLIO-8221Drug

    intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Type, incidence, severity, and seriousness of adverse events (AEs)Time frame: Through end of treatment, up to approximately 2 years.
  2. Type, incidence, and severity of laboratory abnormalitiesTime frame: Through end of treatment, up to approximately 2 years.
  3. Incidence of dose limiting toxicities dose (RP2D) of CLIO-8221Time frame: From first dose through study day 21.

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • DFCI

    Boston, Massachusetts · Not yet recruiting

  • Sarah Cannon Research Institute 335 24th Avenue North, Suite 400

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • START San Antonio

    San Antonio, Texas · Recruiting

  • START Mountain

    West Valley City, Utah · Recruiting

  • Scientia Clinical Research

    Randwick, New South Wales, Australia · Recruiting

  • Integrated Clinical Oncology Network Pty Ltd

    South Brisbane, Queensland, Australia · Recruiting

  • Peter Maccallum Cancer Centre

    Box Hill, Victoria, Australia · Recruiting

  • AlfredHealth

    Heidelberg, Victoria, Australia · Recruiting

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Linear Clinical Research Ltd

    Nedlands, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.